Advertisement

Chemotherapy pp 425-434 | Cite as

CIS-Platinum Diamminodichloride in the Treatment of Squamous Cell Carcinoma and Other Malignant Diseases

  • Ellen Loeb
  • J. M. Hill
  • Ayten MacLellan
  • N. O. Hill
  • M. D. Khan
  • J. J. King
  • R. Speer
  • H. Ridway
Part of the Chemotherapy book series (CT, volume 8)

Abstract

Two Hundred Nineteen (219) patients with various malignant diseases have been treated with cis-platinum diamminodichloride (PDD) during the last 4 years at the Wadley Research Institute. Early animal trials were done by Rosenberg (1)(5) et al. and Speer and Ridgway (11). Clinical usefulness of PDD has been shown by Hill (10) et al.,Talley (6),Welsch (7),(9) and Higby (13). Commonly employed dosage of PDD was 1/2 mg. to 2.5 mg/kg. Schedules have varied from 1/2 mg/kg. b.i.d. to the maximum single dose of 2.5 mg/kg. Total course doses varied ordinarily from 2 to 4 mg/kg. with an interval between courses of at least one month. Treatment was pursued until limiting toxicity or complete remission was observed. The toxic reaction causing the most concern is dose related renal tubular damage. BUN, creatinine, uric acid and creatinine clearance were closely followed. Urine creatinine clearance less than 50 cc/min.disqualified the patient from PDD treatment. Side effects related to hypersensitivity were only seen in one case recently reported by Dr.Khan (15) et al. PDD was used alone and in combination with other drugs such as amethopterin (AME) cyclophosphamide, thioguanine (Protocol designated as PACT) or followed by 5 FU, cyclophosphamide, vincristine, AME, given over 5 days or bleomycin, vincristine or vinblastine.

Keywords

Squamous Cell Carcinoma Slight Improvement Good Improvement Squamous Cell Carcinoma Patient Antineoplastic Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    Rosenberg, B., Van Camp, L. and Krigas, T.,Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205,p. 698, 1965PubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg, B., VanCamp, L., Grimley, E.B. and Thomson, A.J. The inhibition of growth of cell division in Escherichia coli by different ionic species of platinum complexes. J.of Biol.Chem. 242, No. 6, p.1347,1967Google Scholar
  3. 3.
    Rosenberg, B., Renshaw, E., VanCamp, L., Hartwick, J. and Drobuik, J. Platinum induced filamentous growth in Escherichia coli. J. of Bacteriology 93, p. 716,1967.Google Scholar
  4. 4.
    Rosenberg, B., VanCamp, L., Trosko, J.E. and Mansour, V.H. Platinum Compounds:A new class of potent antitumor agents. Nature 222, p.385,1969PubMedCrossRefGoogle Scholar
  5. 5.
    Rosenberg, B.and VanCamp, L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Research, 30, p. 1799,1970PubMedGoogle Scholar
  6. 6.
    Talley, R.W. Chemotherapy of a mouse reticulum cell sarcoma with platinum salts. Abs.Proc.of the A.A.CR.,11,61st annual meeting 1970Google Scholar
  7. 7.
    Welsch, C.W. Effects of cis-platinum diamminodichloride II on growth of 7, 12 dimethylbenzanthracene (MBA) induced tumors in female rats. Abs.proc. A.A.C.R., 12, 1971Google Scholar
  8. 8.
    Welsch, C.W. Growth inhibition of rat mammary carcinoma induced by cis-platinum diamminodichloride.J.Nat.Cancer Inst.47,p.1071, 1971PubMedGoogle Scholar
  9. 9.
    Welsch, C.W. cis-Platinum diamminodichloride (II) induced regression of carcinogen induced rat mammory tumors. Advances in Antimicrobial and Antineoplastic Chemotherapy, Vol. II, Univ. Park Press, Balt., p. 255, 1972.Google Scholar
  10. 10.
    Hill, J.M., Speer, R.J., Loeb, E., MacLellan, A., Hill, N.O. and Khan, A. Clinical experience with cis-platinous diamminodichloride (PDD).Advances in Antimicrobial and Antineoplastic Chemotherapy, Vol. II, Univ.Park Press, Balt., p. 255, 1972.Google Scholar
  11. 11.
    Speer, R.J., Lapis, S., Ridgway, H., Meyers, T.D. and Hill, J.M. cis-Platinous diammine dichloride (PDD) in combination therapy of leukemia L1210. Advances in Antimicrobial and Antineoplastic Chemotherapy, Vol. II, Univ. Park Press, Balt., p.254,1972Google Scholar
  12. 12.
    Hill, J.M.; Loeb, E.; MacLellan, A.; Hill, N.O.; Khan, A. and Kogler, J. Further clinical experience with cis-platinous diaminodichloride.,“Platinum Coordination Complexes in Cancer Chemotherapy”(Ed. by T.A. Connors and J.J. Roberts)Springer-Verlag, Heidelberg, in press,1974.Google Scholar
  13. 13.
    Higby, D.J.; Wallace, H.J.; Albert, D. and Holland, J.F. Diamminodichloroplatinum in the chemotherapy of testicular tumors. J.of Urology, 112, p. 100,1974.Google Scholar
  14. 14.
    Talley, R.W.; O’Bryan, R.M.; Gutterman, J.; Brownlee, R.W.; McCredie, K.B. Phase I clinical evaluation of toxic effects of platinum diamminodichlorocis. Cancer Chemotherapy Reports, Part I, 57, No. 4, 1973.Also in “Platinum Coordination Complexes in Cancer Chemotherapy”(Ed. by T.A.Connors and J.J. Roberts)Springer-Verlag,Heidelberg, 1974 in press.Google Scholar
  15. 15.
    Khan, A., Grater, W., Hill, J.M., Loeb, E., MacLellan, A.S.; Hill, N.O. Atopic Hypersensitivity to cis-Dichlorodiammine Platinum II and Other Platinum Complexes. Cancer Research, in press, 1975.Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Ellen Loeb
    • 1
  • J. M. Hill
    • 1
  • Ayten MacLellan
    • 1
  • N. O. Hill
    • 1
  • M. D. Khan
    • 1
  • J. J. King
    • 1
  • R. Speer
    • 1
  • H. Ridway
    • 1
  1. 1.Granville C.Morton Cancer and Research Hospital of the Wadley Institutes of Molecular MedicineDallasUSA

Personalised recommendations